Lawrence Karsh, MD, FACS

Financial relationships

  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (Oncology)
    Ineligible company:
    Clovis
    Date added:
    Date updated:
    09/14/2023
  • Attribution:
    Self
    Type of financial relationship:
    Scientific Study or Trial (Oncology)
    Ineligible company:
    Exact Sciences
    Date added:
    Date updated:
    09/14/2023
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (Oncology)
    Ineligible company:
    Tolmar
    Date added:
    Date updated:
    09/14/2023
  • Attribution:
    Self
    Type of financial relationship:
    Scientific Study or Trial (Oncology)
    Ineligible company:
    Exelexis
    Date added:
    Date updated:
    09/14/2023
  • Attribution:
    Self
    Type of financial relationship:
    Scientific Study or Trial (Oncology)
    Ineligible company:
    Epizyme
    Date added:
    Date updated:
    09/14/2023
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (Oncology)
    Ineligible company:
    Sesen
    Date added:
    Date updated:
    09/14/2023
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (Oncology)
    Ineligible company:
    Merck
    Date added:
    Date updated:
    09/14/2023
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (Oncology)
    Ineligible company:
    Kiadis
    Date added:
    Date updated:
    09/14/2023
  • Attribution:
    Self
    Type of financial relationship:
    Scientific Study or Trial (Oncology)
    Ineligible company:
    Tavanta
    Date added:
    Date updated:
    09/14/2023
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (Oncology)
    Ineligible company:
    Boston Scientific
    Date added:
    Date updated:
    09/14/2023

Pages

Return to The Changing Face of Advanced Prostate Cancer 2022 Webcast (2022)